Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Type II NADH:quinone oxidoreductase (NDH-2) is a peripheral membrane enzyme that serves as a critical component of the respiratory chain in various pathogenic bacteria and protozoa, such as Mycobacterium tuberculosis and Plasmodium falciparum (PubMed: 27001632, PNAS: 10510271). Unlike the multi-subunit, proton-pumping Type I NADH dehydrogenase (Complex I) found in humans, NDH-2 is a single-subunit, non-proton-pumping flavoprotein that utilizes a non-covalently bound FAD cofactor to catalyze the oxidation of NADH and the reduction of quinones (UniProt: P0A768, Wikipedia). It is essential for maintaining the cellular NADH/NAD+ redox balance and driving the electron transport chain, particularly in organisms that lack Complex I (PubMed: 26854231). Because NDH-2 is functionally and structurally distinct from human mitochondrial enzymes, it is considered a high-value target for the development of selective antimicrobial and antimalarial agents (NIH: PMC4826135). Therapeutic candidates, including phenothiazines and quinolone derivatives, target the enzyme's quinone-binding site to disrupt energy metabolism and induce pathogen lethality (PubMed: 28252965, RSC: 2026-01-05). The absence of this enzyme in human mitochondria minimizes the risk of direct mitochondrial toxicity, although potential cross-reactivity with human cytosolic homologs remains a consideration for drug design (Wikipedia, PubMed: 26854231).
Inhibitors of NDH-2 typically function through competitive inhibition at the quinone-binding site (Q-site), blocking the transfer of electrons from the FAD cofactor to the quinone pool (PubMed: 28252965). This action disrupts the respiratory chain, leading to a depletion of intracellular ATP and an imbalance in the NADH/NAD+ ratio, which ultimately results in the death of the pathogenic organism (PNAS: 10510271, NIH: PMC4826135).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Type II NADH:quinone oxidoreductase (NDH-2) (NDH-2).